Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.98% | 17.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.74% | 149.70% | |||
| Operating Income | -26.74% | -149.70% | |||
| Income Before Tax | -27.06% | -249.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.06% | -249.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.06% | -249.72% | |||
| EBIT | -26.74% | -149.70% | |||
| EBITDA | -26.73% | -150.02% | |||
| EPS Basic | -5.85% | -94.94% | |||
| Normalized Basic EPS | -5.85% | -94.94% | |||
| EPS Diluted | -5.85% | -94.94% | |||
| Normalized Diluted EPS | -5.85% | -94.94% | |||
| Average Basic Shares Outstanding | 20.04% | 79.40% | |||
| Average Diluted Shares Outstanding | 20.04% | 79.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||